Fondaparinux was a regular mention in Dr. Reddy investor and press presentations after its launch until the 3rd quarter of the 13/14 financial year. At that point they seemed to lose interest and reported instead on other generics.
As far as i can see the mention of the 51% market share for Fonda is the first time they have mentioned it in any presentations since the beginning of 2014.
Rev
